Testing stem cell “package” therapy for severe skin blistering
Part of Genetic & congenital, Skin clinical trials.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 6 months old at the time of screening
- Have a confirmed DEB diagnosis from genetic testing or special skin testing
- Have two similar open skin wounds for at least 4 weeks, each about 10–50 cm² and at least 4 inches apart
- Avoid non-routine treatments on the two study wounds for the past 3 months, except standard care (infection control, numbing/pain medicine if needed)
- Females who could become pregnant must have a negative pregnancy test and agree to effective birth control
- Be willing and able to follow study rules and visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
Hear when a new Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.